ORIC Pharmaceuticals' Upcoming Investor Conference Engagements
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a promising clinical-stage oncology company, is dedicated to tackling therapeutic resistance in cancer treatment. This June, ORIC is excited to present at key investor conferences designed to connect with industry stakeholders and showcase its innovative approaches to cancer care.
Scheduled Conferences
Management will actively participate in two significant conferences:
Jefferies Global Healthcare Conference
On June 4, 2025, ORIC will engage with investors during a fireside chat at the Jefferies Global Healthcare Conference. This discussion is set to take place at 12:50 p.m. ET, where the company will share insights into its ongoing research and development efforts.
Goldman Sachs 46th Annual Global Healthcare Conference
Following the Jefferies event, ORIC is also slated to present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 10:00 a.m. ET. These conferences present an excellent opportunity for ORIC to communicate its strategies and clinical advancements directly to its investors and analysts.
Webcasts for Investor Accessibility
For those who cannot attend in person, webcasts of these discussions will be available through the investor section of ORIC's official website. Furthermore, replays of these webcasts will be provided for 90 days post-event, ensuring all interested parties can catch up on the insights shared during the presentations.
Company Overview
ORIC Pharmaceuticals is committed to enhancing patient outcomes by Overcoming Resistance In Cancer. The company’s pipeline includes promising drug candidates such as ORIC-944, an innovative allosteric inhibitor designed for the treatment of prostate cancer, and ORIC-114, a drug specifically aimed at targeting genetically defined cancers through its action on EGFR and HER2 mutations.
ORIC's approach combines robust scientific research with clinical development to provide targeted therapies that aim to overcome common cancer resistance mechanisms. By investing in areas of significant unmet medical need, ORIC is positioned to make substantial contributions to the oncology landscape.
Stay Informed with ORIC Pharmaceuticals
ORIC Pharmaceuticals has a dual-base operation in South San Francisco and San Diego, California, reflecting its commitment to being at the forefront of cancer research. For the latest information, updates, and details about ongoing and upcoming projects, interested parties are encouraged to visit the official website and follow ORIC on various social platforms.
Contact Information
For inquiries, please reach out to:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
Frequently Asked Questions
What is the focus of ORIC Pharmaceuticals?
ORIC Pharmaceuticals specializes in developing treatments that target resistance mechanisms in cancer therapies.
When will ORIC participate in the investor conferences?
ORIC will participate in the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Conference on June 10 in 2025.
How can I access ORIC's investor presentations?
Webcasts of the investor presentations will be available on their official website for 90 days after the events.
What are the key products being developed by ORIC?
ORIC is currently developing ORIC-944 for prostate cancer and ORIC-114, targeting specific genetic mutations in different cancers.
Who can I contact for more information about ORIC?
Inquiries can be made through Dominic Piscitelli, CFO, via the provided email addresses.
